Cocrystal cuts spending, advances trials but faces cash crunch; financing needed

Cocrystal Pharma, Inc. (NASDAQ: COCP)

Short take: management cut operating spend and advanced clinical work (CDI‑988 Phase 1; CC‑42344 Phase 2a), but cash burn remains material and auditors/management flag a going‑concern-additional financing is required within 12 months.

Key facts and figures (as reported, in thousands)

* Cash (June 30, 2025): $4,766

* Cash and restricted cash (June 30, 2025): $4,841

* Tax credit receivable: $1,642

* Total assets: $8,505

* Total liabilities: $3,172

* Stockholders' equity: $5,333

* Accumulated deficit: $(337,774)

* Net loss - three months ended June 30, 2025: $(2,055); prior year $(5,343)

* Net loss - six months ended June 30, 2025: $(4,356); prior year $(9,299)

* Net loss per share - three months: $(0.20); prior year $(0.53)

* Weighted average common shares outstanding: 10,174

* Research & development - three months ended June 30, 2025: $1,122 (prior $4,308)

* Total operating expenses - three months: $2,108 (prior $5,448)

* Net cash used in operating activities - six months ended June 30, 2025: $(5,094)

* Outstanding stock options: 537,491; unvested RSUs: 155,000

What's happening inside the company

* Clinical progress: CDI‑988 (norovirus/coronavirus protease inhibitor) completed Phase 1 SAD/MAD cohorts with favorable safety/tolerability up to 1,200 mg; CC‑42344 (influenza PB2 inhibitor) completed Phase 2a enrollment but study faced low infectivity requiring protocol actions to obtain analyzable antiviral data.

* Cost reduction: R&D and G&A spending fell materially year‑over‑year - operating expenses roughly halved versus prior comparable periods.

* Liquidity pressure: cash burn remains ~ $5.1M over six months; management states current resources likely insufficient to fund operations beyond 12 months and additional capital will be needed.

* Financing runway: company has historically relied on equity raises and an ATM program (total ATM proceeds to date ~$2,226). No ATM sales in the six months ended June 30, 2025.

* Governance/related parties: leases include related‑party landlord (director/major stockholder); related party lease expense ~ $32 for the six months.

Positive aspects of the income statement

* Meaningful reduction in operating spend - R&D down from $4,308 to $1,122 (quarterly) and from $7,258 to $2,482 (six months), reflecting lower clinical spend.

* Lower net loss: three‑month net loss narrowed to $(2,055) from $(5,343); six‑month loss down to $(4,356) from $(9,299) - progress toward burn control.

* Other income was positive (foreign exchange gain and interest income partly offset), helping reduce net loss slightly.

Negative aspects of the income statement

* Still unprofitable: continuing net losses and negative operating cash flow - no revenue reported.

* Large accumulated deficit: $(337,774) (in thousands) signals long history of losses and capital reliance.

* Cash generation insufficient: operating cash use $(5,094) in six months and cash balance ($4,766) likely insufficient for the next 12 months per management - financing risk is immediate.

* Potential dilution: available equity plans (2025 Plan approved with 1,500,000 initial plan shares) and outstanding ATM can dilute current holders if used to raise capital.

Bottom line

Cocrystal is executing on clinical programs and has materially cut near‑term spending, which reduced losses. However, the company remains pre‑revenue, continues to burn cash, and explicitly states it does not have sufficient resources to operate beyond the next 12 months without raising funds - the primary risk for investors today.